Targeted LNP PEG Compounds for Stable Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The delivery of nucleic acid molecules to target cells is complicated by their relative instability and low cell permeability, necessitating the development of targeting compounds and compositions to facilitate effective delivery.
Innovation Solution
The development of targeting compounds, such as those of Formula I, which are incorporated into targeted lipid assemblies (TLAs) to enhance the delivery of therapeutic or prophylactic payload molecules, including nucleic acid molecules, to specific cells like hepatocytes, utilizing components like ionizable lipids, structural lipids, and PEG-lipids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If nucleic acid molecules are delivered directly to target cells, then the delivery process is simple, but the delivery efficiency is low due to instability and low cell permeability
Solution Approach 1:
The patent employs lipid nanoparticle composite structures that encapsulate nucleic acid molecules within a protective lipid bilayer matrix. This composite material provides both structural stability to protect the nucleic acid from degradation and facilitates cellular uptake through the lipid composition, thereby simultaneously improving delivery efficiency and molecular stability.
Solution Approach 2:
The patent introduces targeting ligands as intermediary molecules that mediate between the nucleic acid payload and the target cell surface receptors. These ligands bind to specific cell surface markers (such as ASGPR on hepatocytes) and facilitate selective cellular uptake, improving both delivery efficiency to target cells and the stability of the delivery complex during circulation.
2Measurement precision
If targeting compounds are incorporated into lipid assemblies, then the targeting precision is improved, but the device complexity increases
Solution Approach 1:
The patent divides the delivery system into distinct functional segments: a core lipid nanoparticle structure for protection and delivery, surface-attached targeting ligands for precision targeting, and optional PEGylated components for stability. This segmentation allows each component to be optimized independently while maintaining overall system functionality, achieving high targeting precision without excessive complexity.
Solution Approach 2:
The patent designs modular targeting compounds that can be applied universally across different nucleic acid delivery applications. The same lipid nanoparticle platform with interchangeable targeting ligands can deliver various nucleic acid payloads (siRNA, mRNA, CRISPR components) to different target cells by simply changing the ligand module, thereby achieving high targeting precision without proportionally increasing system complexity.
Data Source
AI summary
Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and/or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.